Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Software - Application
P/S (TTM)
6.9
EV / FCF (TTM)
57.2
Enfusion, Inc. supplies cloud-based software solutions designed for the investment management sector, operating throughout the United States, Europe, the Middle East, Africa, and the Asia Pacific. Its product suite includes a sophisticated portfolio management system, which establishes an instant and comprehensive investment record. This system incorporates valuation and risk assessment tools, allowing chief investment officers (CIOs) and portfolio managers to analyze aggregated or granular portfolio data. The company also offers an order and execution management system, enabling portfolio managers, traders, compliance teams, and analysts to electronically transmit and manage trade orders across various asset classes. This system simultaneously enforces trading regulations and internal operational guidelines. Additionally, Enfusion provides an accounting and general ledger system that serves as a real-time financial book of record, vital for chief financial officers (CFOs), chief operating officers (COOs), accountants, and operations teams. Furthermore, the Enfusion analytics system empowers CIOs, portfolio managers, traders, and analysts to scrutinize portfolios over different timeframes and automatically generate customized visual reports for both internal and external stakeholders. Complementing these software offerings, Enfusion also delivers technology-powered and managed services. Enfusion Inc. was founded in 2021 and is headquartered in Chicago, Illinois.
cwan.comNo one on the platform currently holds ENFN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 334,978 | $3.7M |
| Execution date | Ratio |
|---|---|
| 2006-09-18 | 1-for-28reverse |
No one on the platform has traded ENFN yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.0% | — | — | — | ||
| Rev. Growth % | 15.5% | 27.8% | ||||
| Profit Margin % | 1.4% | -50.3% | ||||
| Free Cash Flow Margin % | 15.4% | 3.4% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +1.3% on the P/E track.
At today's price, your expected annual return is +7.1% on the P/E track.
At today's price, your expected annual return is +12.2% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $278M | +17.2% | $0.37 | $0.31–$0.46 | 29.0× | 3 |
| 2027 | $312M | +12.4% | $0.39 | $0.37–$0.41 | 27.5× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-05-08 | $0.06 | $-0.01 | -116.7% |
| 2025-03-03 | $0.07 | $0.03 | -57.1% |
| 2024-11-04 | $0.06 | $0.05 | -16.7% |
| 2024-08-06 | $0.06 | $0.05 | -16.7% |
| 2024-05-09 | $0.04 | $0.06 | +65.5% |
| 2024-03-12 | $0.06 | $0.04 | -33.3% |
| 2023-11-07 | $0.05 | $0.04 | -20.0% |
| 2023-08-08 | $0.04 | $0.04 | +0.0% |
| $98M |
| — |
| MLMoneyLion Inc. | $85.90 | +0.76% | $972M | — |
| MODNModel N, Inc. | $30.00 | +0.10% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
$ENFN Enfusion should be a lesson to every board member of every publicly traded company, don’t hire a moron like Enfusion did for a CFO who had no experience in transactions like this. What an absolute disaster.
View on StockTwits ↗
M&A Enfusion $ENFN merger with Clearwater Analytics $CWAN effective today Final exchange ratio (for prior ENFN holders) 1. $5.85 plus 0.2159 shares of CWAN 2. 0.4676 shares of CWAN 3. $10.87 cash More Information : https://www.sec.gov/Archives/edgar/data/1866368/000119312525083584/d948507d425.htm
View on StockTwits ↗
$ENFN Diving deep into ENFN's strategic moves. Clearwater acquisition looks promising. Watching for synergy potential and market reaction. insightful writeup: https://beyondspx.com/article/enfusion-inc-enfn-unlocking-value-through-strategic-partnerships
View on StockTwits ↗
$ENFN - Enfusion Inc. Class A Common Stock - 10K - Updated Risk Factors Enfusion's 2025 10-K Risk Factors highlight merger uncertainties, cloud tech adoption challenges, reliance on third-party IT, regulatory scrutiny, stock volatility, and increased legal and financial burdens post-emerging growth status. #Risk https://d-risk.ai/ENFN/10-K/2025-03-03
View on StockTwits ↗
$ENFN tightening up after make a new 52 week high. Looking for that leg up
View on StockTwits ↗
$ENFN in some books you come up as a strong one. when will you start your real move?
View on StockTwits ↗$ENFN / $CWAN - HSR File By Date MergerBrief.com
View on StockTwits ↗
$ENFN still pounding the table lol 11.5 -12 level may take some time
View on StockTwits ↗
$ENFN (+11.7% pre) $CWAN Clearwater Analytics acquires software maker Enfusion for $1.5 bln to drive global expansion - Reuters https://ooc.bz/l/52867
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.